

## IN THE CLAIMS

Under 37 C.F.R. § 1.121(c), please amend the claims as indicated below; a complete listing of the claims is provided pursuant to 37 C.F.R. § 1.121(c)(1):

1.(Currently amended) A An isolated polynucleotide comprising the nucleotide sequence ~~shown in~~ of SEQ ID NO:2 or a ~~part portion~~ thereof, wherein SEQ ID NO. 2 corresponds to exon 1 beta of the PDGF receptor alpha gene.

2.(Currently amended) A An isolated polynucleotide comprising a nucleotide sequence ~~shown in~~ of SEQ ID NO: 2, in which one or more nucleotides are deleted, substituted, or added, comprising a nucleotide sequence contained in the nucleotide sequence of the sense strand of the PDGF receptor alpha gene or a ~~part portion~~ thereof.

3.(Currently amended) A An isolated polynucleotide comprising a nucleotide sequence complementary to the polynucleotide or ~~part portion~~ thereof of claim 1.

4.(Currently amended) A method for suppressing expression of the PDGF receptor alpha gene comprising targeting mRNA including exon 1 beta among mRNAs of the PDGF receptor alpha gene using the substance of claim 7.

5.(Original) The method of claim 4, wherein antisense nucleotides, a ribozyme, a maxizyme, or an RNAi is used.

6.(Original) The method of claim 4, wherein DNA that encodes an antisense RNA, a ribozyme, a maxizyme, or an RNAi is used.

7.(Currently amended) A substance for suppressing expression of the PDGF receptor alpha ~~comprising targeting gene~~ wherein said substance targets mRNA containing exon 1 beta among mRNAs of the PDGF receptor alpha gene.

8.(Original) The substance of claim 7, which is antisense nucleotides, a ribozyme, a maxizyme, or an RNAi.

9.(Original) The substance of claim 7, which is a DNA that encodes an antisense RNA, a ribozyme, a maxizyme, or an RNAi.

10.(Currently amended) An agent for suppressing expression of the PDGF receptor alpha gene comprising the substance of claim 7 as an active ingredient.

11.(Currently amended) A therapeutic agent for treating cancer comprising the agent of claim 10.

12.(Currently amended) A therapeutic method for treating cancer, wherein the agent of claim 10 is used.

13.(Currently amended) A An isolated polynucleotide comprising a nucleotide sequence complementary to the polynucleotide or ~~part~~ portion thereof of claim 2.